

Results of Bladder biopsy clinical trial presented at The Israeli Urological Association Annual Meeting (Eilat, Israel)

Zetiq Technologies Ltd. ("Zetiq"), a subsidiary of Bio-Light Ltd. (TASE: BOLT) and a developer of early cancer diagnosis tools, announces that the results of its pilot bladder biopsy clinical trial were presented at The Israeli Urological Association Annual Meeting held in Eilat, Israel on December 07, 2010.

The oral presentation titled "Innovative cell staining technology (Zetiq) for discriminating normal from neoplastic cells in bladder biopsies" was delivered by Dr. Ofer Yosepovich from the Urology Department at Rabin MC, Israel.

"The presentation of our bladder cancer diagnosis data at this event provided us with the opportunity to update the bladder scientific community with our positive progress in the field of early bladder diagnosis", said Dr. Adi Elkeles, Zetiq CEO.

About Zetiq:

Zetiq Technologies Ltd. develops effective cancer diagnostic tools. A significant medical need exists for early stage diagnostic tools for screening, monitoring or diagnosing cancer. Zetiq offers unique advantages in this market with its proprietary CellDetect® technology for differential staining and morphological visualization to differentiate between non cancer cells and a wide variety of cancer indications. The Company's products alleviate the process of locating and identifying suspected cancer cells, reduce error, simplify the process and have a potential to be fully automated.

Zetiq is a subsidiary of Bio-Light Life Science Investments, a management and holding company specializing in biomedical technologies. Bio-Light is traded on the Tel Aviv Stock Exchange under the symbol TASE: BOLT.

For further information please contact:

Dr. Adi Elkeles

CEO

Zetiq Technologies Ltd.

www.zetiq.co.il

adi@bio-light.co.il